Imagine managing Crohn’s disease symptoms with something as simple as adjusting your eating habits. Sounds too good to be true, right? But here’s where it gets groundbreaking: a recent U.S. study has uncovered that a short-term, calorie-restricted diet could significantly ease the physical symptoms and biological markers of mild-to-moderate Crohn’s disease (CD). And this isn’t just about feeling a little better—it’s about measurable, science-backed improvements.
Participants in the study followed a fasting-mimicking diet (FMD) for just five days each month, consuming between 700 to 1,100 calories daily during those days, and then returned to their normal eating habits for the rest of the month. The results? After only three months, nearly 70% of those on the FMD achieved a clinical response—defined as a reduction of at least 70 points on the Crohn’s Disease Activity Index (CDAI)—compared to less than 44% in the control group. Even more striking, around 65% of the FMD group reached clinical remission (a CDAI of 150 or less), while only 38% of the control group did.
But here’s where it gets controversial: Could something as straightforward as calorie restriction really rival traditional medications? The study also found significant reductions in inflammatory biomarkers like faecal calprotectin, which dropped by 22% in the FMD group compared to an 8% increase in the control group. Nearly 40% of FMD participants saw a 50% or greater decline in faecal calprotectin, versus just 6% in the control group. While changes in C-reactive protein narrowly missed statistical significance, the overall trend was clear: this diet isn’t just a fad—it’s a potential game-changer.
Professor Sidhartha Sinha, the study’s senior author, expressed pleasant surprise at the results: ‘We noticed clinical benefits even after just one FMD cycle.’ But it’s not all smooth sailing. Dietary studies are notoriously tricky due to self-reporting and the inability to blind participants. Yet, this trial managed to demonstrate objective improvements in inflammation and symptoms, making it a standout in the field.
And this is the part most people miss: The benefits weren’t uniform across all participants. Those with mild CD saw a 75% clinical response rate with FMD compared to 48% in the control group, while those with moderate CD saw 57% versus 11%. Participants with colonic or ileocolonic disease also responded better to FMD than those with isolated ileal disease. Interestingly, the diet was most effective for those not on any medical therapy, raising questions about its role as a standalone or complementary treatment.
So, what’s the catch? The study found that clinical response faded after a three-month washout period, suggesting that ongoing FMD cycles might be necessary for sustained remission. Side effects like fatigue and headaches were reported, though no serious issues arose.
Here’s the big question: Could this diet become a mainstream treatment for Crohn’s disease, or is it just a temporary fix? Let us know your thoughts in the comments—do you think calorie restriction could revolutionize how we approach chronic illnesses like CD?
Source: Nature Medicine, 13 January 2026 (https://www.nature.com/articles/s41591-025-04173-w)
